Cefuroxime |

Release form

coated tablets

Packing

10 pcs.

Pharmacological action

Zinnat is a second-generation cephalosporin antibiotic for oral administration. It acts bactericidal, disrupts the synthesis of the bacterial cell wall. It has a wide spectrum of action.

Resistant to most beta-lactamases.

Zinnat is highly active against aerobic gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis (including strains resistant to penicillins and with the exception of rare methicillin-resistant strains), Streptococcus pyogenes, Streptocococcus mucosa (Streptocococcus b) ), Bordetella pertusis of aerobic Gram-negative bacteria: Escherichia coli, Klebsiella spp., Proteus mirabilis, Providencia spp., Proteus rettgeri, Haemophilus influenzae (including ampicillin-resistant strains), Haemophilus parainfluenzae (including ampicillin rachis), Neisseria gonorrhoeae (including strains, producing and not producing penicillinase), Neisseria meningitidis, Salmonella spp. anaerobic gram-positive bacteria: Peptococcus spp., Peptostreptococcus spp., Clostridium spp, Propionibacterium spp. anaerobic gram-negative bacteria: Bacteroides spp, Fusobacterium spp. also active against Borrelia burgdorferi.

Cefuroxime is resistant to Clostridium difficile, Pseudomonas spp., Campylobacter spp., Acinetobacter calcoaceticus, Listeria monocytogenes, methicillin-resistant strains of Staphylococcus aureus, methicillin-resistant strains of Staphylococcus spp.

In vitro studies have shown that when combining cefuroxime with antibiotics from the aminoglycoside group, an additive effect is observed, and in some cases, synergism.

Indications

Treatment of infectious and inflammatory diseases caused by drug-sensitive microorganisms:

respiratory tract infections (including acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess, postoperative chest infections) ear

infections throat, nose (including sinusitis, tonsillitis, pharyngitis, acute otitis media)

infections of the genitourinary system (including acute and chronic pyelonephritis, cystitis, urethritis, asymptomatic bacteriuria)

infection skin and soft tissues (including furunculosis, pyoderma, impetigo)

gonorrhea (including acute uncomplicated gonococcal urethritis and cervicitis)

treatment of Lyme disease at an early stage and subsequent prevention of late manifestations in adults and children over 12 years of age.

Contraindications

Hypersensitivity to the antibiotics of the cephalosporins group.

Use with caution in the first trimester of pregnancy and during lactation.

Special instructions

With prolonged use of Zinnat, increased growth of resistant microorganisms (Candida, Enterococci, Clostridium difficile) is possible, which may require discontinuation of treatment.

When diarrhea develops with antibiotics, including Zinnata, it should be borne in mind the possibility of developing pseudomembranous colitis.

During treatment with Zinnat Lyme disease, a Jarish-Gersheimer reaction is sometimes observed. This reaction is a direct consequence of the bactericidal action of Zinnat on the pathogen - spirochete Borrelia burgdorferi. Patients need to be explained that this is a frequent and common, spontaneous consequence of antibiotic Lyme disease treatment.

Composition

1 tablet contains cefuroxime 250mg

adjuvants:

MCC,

croscarmellose sodium,

sodium lauryl sulfate,

vegetable oil hydrogenated,

colloidal silicon dioxide,

methylhydroxypropylcellulose,

propylene glycol,

methyl parahydroxybenzoate,

propyl parahydroxybenzoate,

Opaspray white

Dosage and administration of

A single dose for adults and children over 12 years of age is usually 250 mg 2 times a day.

In severe infections of the lower respiratory tract - 500 mg 2 times a day.

In case of urinary tract infections, 125 mg 2 times a day are prescribed,

in pyelonephritis - 250 mg 2 times a day.

In the treatment of uncomplicated gonorrhea, 1 g is prescribed once.

In Lyme disease - 500 mg 2 times a day for 20 days.

Side effects of the

From the digestive system: nausea, vomiting, diarrhea, a temporary increase in the activity of liver enzymes (ALT, AST, LDH), jaundice, cases of pseudomembranous colitis are described.

From the hemopoietic system: hemolytic anemia, eosinophilia, neutropenia, thrombocytopenia, leukopenia (sometimes pronounced).

Allergic reactions: skin rash, itching, urticaria, fever, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, serum sickness in isolated cases - anaphylaxis.

From the side of the central nervous system: headache.

Others: Coombs' positive reaction.

Drug Interactions

Simultaneous administration of cefuroxime and probenecide leads to an increase in AUC of cefuroxime by 50%.

Storage conditions

Store at a temperature not exceeding 25 РC.

Deystvuyuschee substances

Cefuroxime

dosage form

tab etki

GlaxoSmithKline, UK